Bain Capital Life Sciences Investors’s C4 Therapeutics CCCC Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$18.9M	Hold	7,171,910	–	–	1.7%	15
2025 Q4	$13.7M	Buy	7,171,910 +6,060,000	+545%	+$14.4M	1.05%	14
2025 Q3	$2.47M	Hold	1,111,910	–	–	0.16%	19
2025 Q2	$1.59M	Hold	1,111,910	–	–	0.2%	20
2025 Q1	$1.78M	Hold	1,111,910	–	–	0.26%	21
2024 Q4	$4M	Hold	1,111,910	–	–	0.47%	21
2024 Q3	$6.34M	Hold	1,111,910	–	–	0.66%	18
2024 Q2	$5.14M	Sell	1,111,910 -30,300	-3%	-$181K	0.56%	19
2024 Q1	$9.33M	Sell	1,142,210 -500,000	-30%	-$3.88M	0.75%	20
2023 Q4	$9.28M	Hold	1,642,210	–	–	0.89%	19
2023 Q3	$3.05M	Hold	1,642,210	–	–	0.34%	29
2023 Q2	$4.52M	Hold	1,642,210	–	–	0.47%	28
2023 Q1	$5.16M	Hold	1,642,210	–	–	0.64%	29
2022 Q4	$9.69M	Hold	1,642,210	–	–	1.08%	23
2022 Q3	$14.4M	Hold	1,642,210	–	–	1.72%	18
2022 Q2	$12.4M	Hold	1,642,210	–	–	1.45%	17
2022 Q1	$39.8M	Hold	1,642,210	–	–	3.87%	9
2021 Q4	$52.9M	Buy	1,642,210 +1	+0%	+$40	4.19%	8
2021 Q3	$73.4M	Hold	1,642,209	–	–	4.55%	8
2021 Q2	$62.1M	Hold	1,642,209	–	–	4.07%	7
2021 Q1	$60.7M	Hold	1,642,209	–	–	3.44%	8
2020 Q4	$54.4M	Buy	+1,642,209	New	+$47.6M	3.42%	8

Other funds holding CCCC

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bain Capital Life Sciences Investors's CCCC Position: Q1 2026 in Review

Bain Capital Life Sciences Investors held its C4 Therapeutics (CCCC) position steady in Q1 2026 at 7,171,910 shares worth $18.9M. The position accounts for 1.7% of the portfolio, ranked #15.

Bain Capital Life Sciences Investors first reported a position in CCCC in Q4 2020 and has held it in 22 quarters since. The position peaked at $73.4M in Q3 2021. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

Bain Capital Life Sciences Investors held 7,171,910 shares of C4 Therapeutics worth $18.9M as of Q1 2026.
Bain Capital Life Sciences Investors left its C4 Therapeutics share count unchanged in Q1 2026.
C4 Therapeutics made up 1.7% of Bain Capital Life Sciences Investors's portfolio in Q1 2026, its #15 holding.
Bain Capital Life Sciences Investors first reported a position in C4 Therapeutics in Q4 2020 and has held it in 22 quarters since.
Bain Capital Life Sciences Investors's C4 Therapeutics position peaked at $73.4M in Q3 2021.
123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2026, filed 15 May 2026.